Joe Oved, MD joins the CHOP Comprehensive Bone Marrow Failure Center

Effective July 1, 2019, Dr. Joe Oved joined the CHOP CBMFC faculty. Dr. Oved recently completed his Fellowship Training at CHOP.

Dr. Oved brings deep expertise to the group, having completed scientific and clinical training that included tenures as a Fulbright Fellow with the Weizmann Institute in Israel, Medical school at NYU with two years as a Howard Hughes Medical Fellow, followed by a Residency in Pediatrics at NYP Weill Cornell Medical College. During his residency, he developed an interest in more translational questions working with Dr. James Bussel, to test a novel combination of dexamethasone and rituximab for pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).

During his fellowship training in Hematology/Oncology, he developed a lasting interest in bone marrow failure and worked with Dr. Tim Olson on several projects. This includes improvement in transplantation strategies with emphasis on CD3+/CD19+ depleted matched and mismatched unrelated donor hematopoietic stem cell transplant with targeted T cell addback in pediatric patients with nonmalignant hematologic disorders. The success of this strategy led to further refinement with TCRab T cell depletion, which is currently an open protocol at CHOP.

In a second project he leveraged the CBMFC registry (which to date has enrolled over >600 patients) where he demonstrated that clonal hematopoiesis in pediatric BMF does not predispose to malignancy.

More recently, Dr. Oved has focused on red cell predominant bone marrow failure syndromes and is collaborating with Dr. Rivella (CHOP) and Dr. Mark Fleming (Boston Children’s Hospital) on preclinical Gene Therapy studies for Congenital Sideroblastic Anemia.

His long-term plan at the Center is to spearhead the development of Cell and Gene Therapy for BMF.